ZBIO (Zenas BioPharma) Deferred Tax : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Zenas BioPharma's change in deferred tax for the three months ended in Dec. 2024 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Zenas BioPharma Deferred Tax Historical Data

The historical data trend for Zenas BioPharma's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Deferred Tax Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Deferred Tax

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Deferred Tax	Get a 7-Day Free Trial				-	-	-	-	-

Zenas BioPharma Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zenas BioPharma Deferred Tax Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.